WINT (Windtree Therapeutics) EBIT per Share : $-847.08 (TTM As of Sep. 2024)

View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics EBIT per Share?

Windtree Therapeutics's EBIT per Share for the three months ended in Sep. 2024 was $-163.22. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-847.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Windtree Therapeutics's EBIT per Share or its related term are showing as below:

WINT's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 5.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Windtree Therapeutics's EBIT for the three months ended in Sep. 2024 was $-2.94 Mil.

Windtree Therapeutics EBIT per Share Historical Data

The historical data trend for Windtree Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windtree Therapeutics EBIT per Share Chart

Windtree Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-77,509.00

-40,522.00

-5,060.25

Windtree Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-735.33	-857.00	1,149.56	-976.42	-163.22

Windtree Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Windtree Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.241	/	0.004
=	-5,060.25

Windtree Therapeutics's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.938	/	0.018
=	-163.22

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-847.08

Windtree Therapeutics (NAS:WINT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Windtree Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Windtree Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622

Website

https://www.windtreetx.com

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Executives

Craig Fraser	director, officer: Chief Executive Officer	AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew	officer: VP, Controller, & CAO	WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck	director	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill	officer: SVP & CFO	4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc.	10 percent owner	7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc.	10 percent owner	7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman	officer: SVP & General Counsel	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis	officer: SVP & COO	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson	officer: SVP, Chief Development Officer	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh	director	75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott	director
Joseph M Mahady	director	16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber	director	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976